- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06767423
Comparing the Effectiveness of Different Appointment Reminder Methods
April 1, 2025 updated by: M. Kit Delgado, MD
Comparative Effectiveness of Targeted Outreach With an Automated Caller for Increasing Appointment Completion: A Randomized Quality Improvement Initiative
Penn Medicine is continually trying to optimize operations and decrease number of patients who do not show up for their appointments.
This has included new changes to text message reminders, implemented as usual care.
At a baseline, less than 75% of scheduled outpatient appointments are actually completed.
This results in longer wait times and decreased access for patients and operational inefficiencies.
The goal of the project is to test whether supplementing standard text message appointment reminders with targeted outreach using an automated phone call to patients with increased risk of not showing up for their appointment (>15% per Epic's Risk of Patient No-Show Model) reduces no show rate (the study's primary outcome) and increases patient appointment completion rate (% of appointments that were completed during scheduled appointment time, a secondary outcome).
Participants will be randomized in a 1:1 ratio to receive either the standard text message or standard text message plus the automated caller.
Eligible patients have already consented to receiving text message reminders from Penn Medicine and must have an in-person appointment scheduled during the study period.
The Access Optimization Group at Penn will be monitoring the randomization and outcomes reporting of whether a patient confirmed, cancelled, or no showed at the scheduled appointment.
All eligible outpatient appointments over a two week period will be included in this operational evaluation.
The Access Optimization Group will then make a decision on which approach to implement as usual care based on the results of this operational evaluation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32925
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Penn Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- in-person appointments
- English or Spanish speakers
- 18 years old or older
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Text Message (Usual Care)
Standard text message appointment reminders to English and Spanish-speaking patients.
Text reminders will go out 3-weeks, 3 days, and 24 hours before the appointment.
|
|
|
Active Comparator: Text Message + Automated Caller (Intervention)
Standard text message appointment reminders to English and Spanish-speaking patients.
Text reminders will go out 3-weeks, 3 days, and 24 hours before the appointment.
If patient has not confirmed their appointment after the 3-week and 3-day reminders, they'll receive an automated caller.
|
Standard text message appointment reminders to English and Spanish-speaking patients.
Text reminders will go out 3-weeks, 3 days, and 24 hours before the appointment.
If patient has not confirmed their appointment after the 3-week and 3-day reminders they will receive an automated caller.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
No Show Rate
Time Frame: Through study completion, on average of 3 weeks
|
Proportion of initially scheduled appointments in which the patient did not show.
|
Through study completion, on average of 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Appointment Completion Rate
Time Frame: Through study completion, on average of 3 weeks
|
Proportion of initial scheduled appointments completed.
|
Through study completion, on average of 3 weeks
|
|
Appointment Cancelation Rate
Time Frame: Through study completion, on average of 3 weeks
|
Proportion of initially scheduled appointments cancelled.
|
Through study completion, on average of 3 weeks
|
|
Appointment Refill Rate
Time Frame: Through study completion, on average of 3 weeks
|
Proportion of cancelled appointments that were refilled.
|
Through study completion, on average of 3 weeks
|
|
Refilled Appointment Completion Ration
Time Frame: Through study completion, on average of 3 weeks
|
Proportion of refilled appointments that were completed.
|
Through study completion, on average of 3 weeks
|
|
Net Appointment Completion Rate
Time Frame: Through study completion, on average of 3 weeks
|
Proportion of appointment slots resulting in a completed appointment.
Includes completed refilled appointments.
|
Through study completion, on average of 3 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 5, 2024
Primary Completion (Actual)
December 5, 2024
Study Completion (Actual)
February 5, 2025
Study Registration Dates
First Submitted
November 13, 2024
First Submitted That Met QC Criteria
January 5, 2025
First Posted (Actual)
January 9, 2025
Study Record Updates
Last Update Posted (Actual)
April 4, 2025
Last Update Submitted That Met QC Criteria
April 1, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Other Study ID Numbers
- IRB # 855257
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Appointment Reminders
-
VA Office of Research and DevelopmentIowa City VA Health Care System; VA Salt Lake City Health Care SystemCompletedAppointment RemindersUnited States
-
The University of Texas Health Science Center,...CompletedAppointment Reminders
-
Beth Israel Deaconess Medical CenterDonald W. Reynolds FoundationCompletedElectronic Medical Record Reminders and Panel Management to Improve Primary Care of Elderly PatientsEMR Reminders to Improve Rates of Recommended CareUnited States
-
Centre d'Investigation Clinique et Technologique...CompletedDuring the Medical Appointment, the Speech Therapist Will Perform Phonetic TestsFrance
-
Children's Hospital Los AngelesRecruitingSelf Efficacy | Health Literacy | Emotional Wellbeing | Health Care Transition Readiness | Appointment AttendanceUnited States
-
Centers for Disease Control and PreventionHealth Resources and Services Administration (HRSA)CompletedPrimary Care Appointment KeepingUnited States
Clinical Trials on Text Message + Automated Caller (Intervention)
-
Emory UniversityNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
Thomas Jefferson UniversityCompletedChronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
Stanford UniversityNot yet recruiting
-
Stanford UniversityCompleted
-
Thomas Jefferson UniversityWithdrawnAcute Myeloid LeukemiaUnited States
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingTobacco-Related CarcinomaUnited States
-
Kessler FoundationUnknownStroke | Cognitive Impairment | Brain Injuries, Traumatic | Medication Adherence | Stroke, Acute | Medication ComplianceUnited States
-
Columbia UniversityNational Cancer Institute (NCI); Makerere UniversityActive, not recruiting
-
University of WashingtonThe Hope FoundationActive, not recruitingInsomnia | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8United States
-
Dokuz Eylul UniversityActive, not recruitingType 2 Diabetes Mellitus (T2DM) | Patient Activation | Diabetes Self-management | Diabetes Mellitus (DM)Turkey